Search results
Showing 1621 to 1635 of 2183 results for guidelines
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.
Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.
factors were taken from recommendation 1.1.6 (developed as part of the 2013 guideline) apart from the level of eGFR which was based on...
What is the clinical and cost effectiveness of opioids for the management of acute sciatica?
prescribed for sciatica. They noted that advice is already included in this guideline for the use of paracetamol for people with low...
What is the clinical and cost effectiveness of antidepressants for the management of sciatica?
prescribed for sciatica. They noted that advice is already included in this guideline for the use of paracetamol for people with low...
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Cabotegravir for preventing HIV-1 in adults and young people (TA1106)
Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.
Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)
This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.
In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. However the guidance review in 2022 recommended it be withdrawn because it was determined that: The existing medical technologies guidance was considered along with other interventions in the update of NICE's guideline on atrial fibrillation. See evidence review A and evidence review B providing the best advice to the NHS about its use. As evident in NICE's guideline on atrial fibrillation, the evidence base and experts’ advice, the landscape for opportunistically detecting atrial fibrillation in primary care has changed significantly since the original guidance, with a wider range of devices for detecting atrial fibrillation now available.
Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .
Prevena incision management system for closed surgical incisions (MIB173)
NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .